Synergistic Stimulation of Mucociliary Clearance to Treat Mucus Obstruction in Cystic Fibrosis and Other Muco-Obstructive Disorders
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsJeffrey J. Wine, Nam Soo Joo, Carlos E. Milla
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating an individual for a muco-obstructive, the methods including: administering to the individual a b-adrenergic agonist or an adenylate cyclase activator, in combination with a cholinergic agonist to treat the individual for the muco-obstructive disorder.
Claims20
A method of treating an individual for a muco-obstructive disorder, the method comprising:
- administering to the individual a β-adrenergic agonist or an adenylyl cyclase activator, in combination with a cholinergic agonist to treat the individual for the muco-obstructive disorder.
The method of any of the preceding claims, wherein the cholinergic agonist is a direct acting cholinergic agonist.
The method of any of the preceding claims, wherein the β-adrenergic agonist and the cholinergic agonist are administered sequentially.
The method of any of the preceding claims, wherein the β-adrenergic agonist and the cholinergic agonist are administered systemically.
The method of any of the preceding claims, wherein the administration does not cause airway smooth muscle contractions.
The method of any of the preceding claims, further comprising administering one or more cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
The method of any of the preceding claims, wherein the administration results in a synergistic increase in mucus transport relative to the mucus transport of either agonist used alone.
The method of any of the preceding claims, wherein the individual is a human.
A pharmaceutical composition comprising:
- a β-adrenergic agonist or an adenylyl cyclase activator;
- a cholinergic agonist;
- and
- a pharmaceutical excipient.
Dependencies are inferred from the claim text.